Cargando…
Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy
To assess the association of the programmed cell death ligand 1 (PD‐L1) with cisplatin‐based neo‐adjuvant chemotherapy (NAC) response, we investigated the level of PD‐L1 and found increased PD‐L1 expression in chemo‐resistant tumors compared with chemo‐sensitive tumors according to RNA‐Seq analysis....
Autores principales: | Zhang, Panpan, Ma, Yuanyuan, Lv, Chao, Huang, Miao, Li, Mingzhen, Dong, Bin, Liu, Xijuan, An, Guo, Zhang, Wenlong, Zhang, Jianzhi, Zhang, Liyi, Zhang, Shanyuan, Yang, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132280/ https://www.ncbi.nlm.nih.gov/pubmed/27581532 http://dx.doi.org/10.1111/cas.13072 |
Ejemplares similares
-
Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients
por: Ma, Yuanyuan, et al.
Publicado: (2016) -
Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy
por: Song, Wu, et al.
Publicado: (2012) -
Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells
por: Yang, Mengqi, et al.
Publicado: (2017) -
Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study
por: Huang, Zekai, et al.
Publicado: (2019) -
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)